Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01873768 · ClinicalTrials.gov registry record · Phase 4

Clinical Efficacy of Tranexamic Acid and ε-Aminocaproic Acid in Reducing Blood Loss Following Total Knee Replacement

A Phase 4 study of Osteoarthritis, sponsored by Miller Orthopedic Specialists.

Completed
Registry status
Phase 4
Development phase
194
Enrollment target
1
Study location

NCT01873768: Completed Phase 4 study of Osteoarthritis, sponsored by Miller Orthopedic Specialists.

NCT01873768 is a Phase 4 study of Osteoarthritis that has completed, run by Miller Orthopedic Specialists. The registered enrollment target is 194 participants, below the 816-participant average among 135 other Osteoarthritis trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01873768, a Phase 4 study of Osteoarthritis, has completed, sponsored by Miller Orthopedic Specialists.

COMPLETED
Registry status
Phase 4
Development phase
194 participants
Enrollment target
1
Study location

Study Summary

Tranexamic acid (TXA) and ε-aminocaproic acid (EACA) are two drugs shown to limit blood loss following major surgery, from cardiac to orthopedic procedures. Yet compared to tranexamic acid (TXA), research on the clinical impact of ε-aminocaproic acid (EACA) in total knee arthroplasty (TKA) is limited. The primary aim of this study is to determine whether TXA and EACA provide similar blood decreasing effects following TKA or whether one drug provides a superior effect over the other in reducing patients' blood loss.

Conditions Studied

Interventions

  • DRUG Tranexamic Acid (TXA)
  • DRUG ε-Aminocaproic Acid (EACA)

Study Locations (1)

Iowa

  • Miller Orthopedic Specialists - Council Bluffs

Trial Details

FieldValue
Enrollment Target 194 participants
Start Date 2014-01
Est. Completion 2015-12
Phase Phase 4
Miller Orthopedic Specialists

1 total trials

What the finished NCT01873768 record still lists

NCT01873768 is an interventional study that assigns participants to a tested intervention. The registered 194 participants enrollment target is mid-sized for trials with a published cap, below the 816-participant average among 135 other Osteoarthritis trials with a reported enrollment target (76% lower).

The record links to 1 condition, with Osteoarthritis appearing as the primary indexed condition, and to 2 interventions - of which Tranexamic Acid (TXA) is the first listed.

NCT01873768 reports a single indexed study location in Iowa.

Frequently Asked Questions

What is clinical trial NCT01873768 about?

NCT01873768 is a clinical study titled "Clinical Efficacy of Tranexamic Acid and ε-Aminocaproic Acid in Reducing Blood Loss Following Total Knee Replacement". Tranexamic acid (TXA) and ε-aminocaproic acid (EACA) are two drugs shown to limit blood loss following major surgery, from cardiac to orthopedic procedures. Yet compared to tranexamic acid (TXA), research on the clinical impact of ε-aminocaproic acid (EACA) in total knee arthroplasty (TKA) is limite...

What is the current status of trial NCT01873768?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 194 participants. The study started on 2014-01. Estimated completion is 2015-12.

What conditions does trial NCT01873768 study?

This clinical trial studies the following conditions: Osteoarthritis.

What interventions are being tested in trial NCT01873768?

The interventions under investigation include: Tranexamic Acid (TXA) (DRUG), ε-Aminocaproic Acid (EACA) (DRUG).

Who is sponsoring clinical trial NCT01873768?

This trial is sponsored by Miller Orthopedic Specialists, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01873768 being conducted?

This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Osteoarthritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01873768's enrollment target sits among peer trials

194 62nd of 135 higher than 74 of 135 other Osteoarthritis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Osteoarthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03593759 · 194 participants · Phase 3

    Cardiac Sarcoidosis Randomized Trial

  • NCT05053152 · 194 participants · Phase 2

    Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study

  • NCT05156112 · 194 participants · NA

    OSA PAP Treatment for Veterans With SUD and PTSD on Residential Treatment Unit

  • NCT05351424 · 194 participants · NA

    AVI Didactic Experience for Latinx Patient Treatment Adherence and Non-English Speaker Trial Enrollment Study in Rad Onc

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01873768, the US trial registry maintained by the National Library of Medicine. NCT01873768 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.